Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue SUPPL. 2, 2005, Pages

  Snyder, Lorraine C ^a   Astsaturov, Igor ^a   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cetuximab; Ligands; Neuroregulins

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; PANITUMUMAB;

BINDING SITE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RASH; REVIEW; SIGNAL TRANSDUCTION; UNITED STATES;

ANTIBODIES, MONOCLONAL; BINDING SITES; COLORECTAL NEOPLASMS; DRUG APPROVAL; EXANTHEMA; GENE AMPLIFICATION; HUMANS; LIGANDS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; SIGNAL TRANSDUCTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 30544450934     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.s.010     Document Type: Article

References (82)

1. Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem 1980; 255:8363-8365.
2. Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980; 255:4834-4842.
3. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307:521-527.
4. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164:769-779.
5. Messa C, Russo F, Caruso MG, et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37:285-289.
6. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284:14-30.
7. Ferguson KM, Berger MB, Mendrola JM, et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003; 11:507-517.
8. Lax I, Fischer R, Ng C, et al. Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. Cell Regul 1991; 2:337-345.
9. Lemmon MA, Bu Z, Ladbury JE, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 1997; 16:281-294.
10. Sibilia M, Fleischmann A, Behrens A, et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 2000; 102:211-220.
11. Domagala T, Konstantopoulos N, Smyth F, et al. Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. Growth Factors 2000; 18:11-29.
12. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61:203-212.
13. Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110:763-773.
14. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-787.
15. Mattoon D, Klein P, Lemmon MA, et al. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc Natl Acad Sci U S A 2004; 101:923-928.
16. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-758.
17. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
18. Weiner LM, Carter P. Tunable antibodies. Nat Biotechnol 2005; 23:556-567.
19. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-311.
20. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
21. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
22. Lutz M, Schoffski, P, Folprecht, G, et al. A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer expressing the epidermal growth factor receptor. Ann Oncol 2002; 13(suppl 5):73.
23. Rosenberg A, Loehrer PJ, Needle MN, et al. Erbitux (IMC-c225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21:135a (Abstract #536).
24. Van Laethem JL, Raoul JL, Mitry E, et al. Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU), and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 2003; 22:264 (Abstract #1058).
25. Bier H, Hoffmann T, Haas I, et al. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998; 46:167-173.
26. Doi T, Ohtsu A, Saijo H, et al. A phase I study of a humanized monoclonal anti-epidermal growth factor (EGFR) antibody "EMD72000 (matuzumab)" administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies. Late-breaking abstract from the 2005 Annual Meeting of ASCO. J Clin Oncol 2005; 23(suppl):3077.
27. Kim T. Technology evaluation: Matuzumab, Merck KGaA. Curr Opin Mol Ther 2004; 6:96-103.
28. Weiner L, Belldegrun A, Rowinsky E, et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. Late-breaking abstract from the 2005 Annual Meeting of ASCO. J Clin Oncol 2005; 23(16 suppl):206s (Abstract #3059).
29. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-286.
30. Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 1990; 87:8602-8606.
31. Modjtahedi H, Moscatello DK, Box G, et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 2003; 105:273-280.
32. Wikstrand CJ, Reist CJ, Archer GE, et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998; 4:148-158.
33. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990; 87:4207-4211.
34. Johns TG, Mellman I, Cartwright GA, et al. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J 2005; 19:780-782.
35. Johns TG, Adams TE, Cochran JR, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004; 279:30375-30384.
36. Jungbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003; 100:639-644.
37. Panousis C, Rayzman VM, Johns TG, et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 2005; 92:1069-1077.
38. Modjtahedi H, Hickish T, Nicolson M, et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73:228-235.
39. Green LL, Su J, Ahluwalia K, et al. Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates. Presented at the 2004 Annual Meeting of the American Association for Cancer Research; March 27-31; Orlando, FL. Abstract #5347.
40. Crombet T, Torres L, Neninger E, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003; 26:139-148.
41. Crombet Ramos T, Figueredo J, Catala M, et al. Treatment of high-grade astrocytic tumors with the humanized anti-EGF-R antibody h-R3 and radiotherapy. Late-breaking abstract from the 2005 Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol 2005; 23(16 suppl):179s (Abstract #2554).
42. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665-19672.
43. Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. J Immunol Methods 2001; 248:1-6.
44. Pfister D, Lipton A, Belt R, et al. A phase I trial of the epidermal growth factor receptor-directed bispecific antibody MDX-447 in patients with solid tumors. Proc Am Soc Clin Oncol 1999; 18:433a (Abstract #1667).
45. Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 1997; 45:210-215.
46. Jung G, Brandl M, Eisner W, et al. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int J Cancer 2001; 91:225-230.
47. Grosse-Hovest L, Muller S, Minoia R, et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci U S A 2004; 101:6858-6863.
48. Braun AH, Dirsch O, Hilger RA, et al. Preclinical evaluation of the combination of epidermal growth factor inhibitor ZD1839 (Iressa) and irinotecan (SN-38) in human colon cancer cells. Proc Am Soc Clin Oncol 2002; 21:83a (Abstract #329).
49. Bridgewater JA, Harrison M, Broby C, et al. Phase I clinical trail of gefitinib and 5FU in patients with 5FU-refractory colorectal cancer. Presented at the 2005 Gastrointestinal Cancers Symposium; January 27-29; Miami, FL. Abstract #292.
50. Oza AM, Townsley C, Siu LL, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22:196 (Abstract #785).
51. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:210a (Abstract #1235).
52. Hanauske AR Diaz-Rubio E, Cassidy J, et al. Erlotinib HCl in combination with FOLFOX4 in patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22:197 (Abstract #789).
53. Longo R, Sarmiento R, Fanelli M, et al. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002; 5:237-256.
54. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1:85-94.
55. Bence AK, Anderson EB, Halepota MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005; 23:39-49.
56. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible, dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23:5305-5313.
57. Belanger M, Jones CM, Germond C, et al. A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU in combination with irinotecan and/or oxaliplatin. Proc Am Soc Clin Oncol 2003; 22:244 (Abstract #978).
58. Hidalgo M, Erlichman C, Rowinsky EK, et al. Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21:65a (Abstract #65).
59. Tejpar S, Van Cutsem E, Gamelin E, et al. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluoruracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). J Clin Oncol 2004; 22:3579.
60. Carter T, Wodicka LM, Sha NP, et al. Inhibition of drug-resistant mutants of ABL, KIT and EGF receptor kinases. Proc Natl Acad Sci U S A 2005; 102:11011-11016.
61. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
62. Barber TD, Vogelstein B, Kinzler KW, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351:2883.
63. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
64. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23:3536-3544.
65. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-3747.
66. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-5101.
67. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 91:208-212.
68. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52:893-901.
69. Johnson GA, Mannel R, Khalifa M, et al. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol 1997; 65:425-429.
70. King AC, Cuatrecasas P. Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem 1982; 257:3053-3060.
71. Defize LH, Boonstra J, Meisenhelder J, et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989; 109:2495-2507.
72. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
73. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
74. Morelli MP, Cascone T, Troiani T, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16(suppl 4):iv61-iv68.
75. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997; 89:341-343.
76. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10:505-510.
77. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-1176.
78. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138:129-131.
79. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601.
80. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
81. Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10:345-356.
82. Calderwood DA. Integrin activation. J Cell Sci 2004; 117:657-666.